États-Unis · Plateformes & données · Briefing.com

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Publié par Briefing.com · États-Unis il y a 11 j

Disc Medicine (IRON) is surging today after announcing that its pivotal Phase 3 APOLLO trial of bitopertin met both co-primary and all secondary endpoints in patients with…

Lire l'article complet sur Briefing.com Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.briefing.com)

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

À lire aussi

Axon Enterprise vs. ServiceNow: Which Industrials Stock Is a Better Buy in 2026?

Tenet Healthcare Q3 Earnings Call Highlights

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

CNBC is at the Fort Lauderdale International Boat Show

Disc Medicine Surges as Phase 3 APOLLO Trial Meets All Primary and Secondary Endpoints (IRON)

Partager

À lire aussi

Axon Enterprise vs. ServiceNow: Which Industrials Stock Is a Better Buy in 2026?

Tenet Healthcare Q3 Earnings Call Highlights

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

CNBC is at the Fort Lauderdale International Boat Show